Home › Funds › Lynx1 Capital Management LP › PRQR
Lynx1 Capital Management LP position in PRQR
PROQR THRAPEUTICS N V · Health Care
Lynx1 Capital Management LP reported holding 1,562,093 shares of PRQR (PROQR THRAPEUTICS N V) in its Q3 2026 13F filing — a position valued at US$2.6M, representing 0.40% of its reported portfolio and ranking #10 among its reported holdings. Lynx1 Capital Management LP has disclosed PRQR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Lynx1 Capital Management LP's PRQR position evolved
Lynx1 Capital Management LP first disclosed a stake in PRQR in Q4 2025 at 68,486 shares (US$138K). The position peaked in Q3 2026 at 1,562,093 shares, worth US$2.6M. Across 4 filings, Lynx1 Capital Management LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,562,093 shares valued at US$2.6M — an increase of 1,040,680 shares quarter over quarter.. Notable position changes include a 661% increase in Q2 2026 (shares fell 11% over the following quarter), a 200% increase in Q3 2026 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 68.49K | $138.34K | New |
| Q1 2026 | 68.49K | $110.95K | Hold |
| Q2 2026 | 521.41K | $969.83K | Add |
| Q3 2026 | 1.56M | $2.59M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PRQR and 13F data
PRQR (PROQR THRAPEUTICS N V) is a Health Care company. 32 other funds we track also report a position in PRQR — the largest reported positions include Privium Fund Management B.V. (US$9.1M), Ikarian Capital, LLC (US$5.7M), Kynam Capital Management, LP (US$2.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PRQR
- Privium Fund Management B.V. 5.47M sh · $9.08M · Q3 2026
- Ikarian Capital, LLC 3.43M sh · $5.69M · Q3 2026
- Kynam Capital Management, LP 1.57M sh · $2.60M · Q3 2026
- DAFNA Capital Management LLC 1.31M sh · $2.18M · Q3 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 1.16M sh · $1.92M · Q3 2026
- Monaco Asset Management SAM 634.92K sh · $1.05M · Q3 2026
- M28 Capital Management LP 599.79K sh · $995.66K · Q3 2026
More on Lynx1 Capital Management LP
FAQ
How long has Lynx1 Capital Management LP held PRQR?
Lynx1 Capital Management LP has disclosed PRQR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Lynx1 Capital Management LP's current position in PRQR?
As of Q3 2026, Lynx1 Capital Management LP holds 1.56M shares of PRQR (PROQR THRAPEUTICS N V), valued at $2.59M, representing 0.40% of its reported portfolio and ranking #10.
Has Lynx1 Capital Management LP been buying or selling PRQR?
In the latest 13F filing (Q3 2026), Lynx1 Capital Management LP increased its position in PRQR. The position peaked in Q3 2026 at 1.56M shares.
Which other funds hold PRQR?
Other major institutional holders of PRQR include Privium Fund Management B.V., Ikarian Capital, LLC, Kynam Capital Management, LP, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.